Effect of cycloxygenase‑2 silencing on the malignant biological behavior of MCF‑7 breast cancer cells

Yang,Sheng; Han,Hui

doi:10.3892/ol.2014.2395

Effect of cycloxygenase‑2 silencing on the malignant biological behavior of MCF‑7 breast cancer cells

Authors:
- Sheng Yang
- Hui Han
View Affiliations

Affiliations: Department of Oncology, The Union Hospital of Fujian Medical University, Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian 350001, P.R. China, Department of Breast Surgery, The Union Hospital of Fujian Medical University, Fuzhou, Fujian 350001, P.R. China
Published online on: July 30, 2014 https://doi.org/10.3892/ol.2014.2395
Pages: 1628-1634

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effect of cyclooxygenase‑2 (COX‑2) silencing on the malignant biological behavior of MCF‑7 breast cancer cells. COX‑2 short hairpin RNA (shRNA) and unassociated sequences were synthesized and a shRNA lentiviral vector was constructed. The vector was transfected into MCF‑7 breast cancer cells, in which clones with stable expression were screened out. The expression of COX‑2 mRNA and protein was silenced using RNA interference (RNAi). Quantitative polymerase chain reaction, western blotting, a mononuclear cell direct cytotoxicity assay (MTT assay), a cell invasion assay and scratch tests were performed to investigate the downregulation of COX‑2 mRNA and protein expression, the proliferative activity and growth rate of MCF‑7 breast cancer cells, the glioblastoma multiforme (GBM) penetrating capacity, the cell movement and migratory capacity, and vascular endothelial growth factor (VEGF)‑A and VEGF‑C protein expression. The results revealed that the sequence‑specific shRNA significantly downregulated the expression of COX‑2 at the mRNA and protein levels. Furthermore, the downregulation of COX‑2 expression markedly decreased the invasive and metastatic capacities of the cells, suppressed the proliferation, decreased the rate of growth, decreased the capacity of GBM penetration and migration, and decreased the protein expression of VEGF‑A and VEGF‑C, the two key factors that regulate tumor angiogenesis and lymphangiogenesis. In conclusion, the RNAi technique effectively silenced COX‑2 gene expression and inhibited MCF‑7 breast cancer cell proliferation, invasion and metastasis by decreasing VEGF‑A and VEGF‑C expression, which regulates tumor angiogenesis and lymphangiogenesis. Therefore, an RNAi technique that targets COX‑2 presents a promising prospect for breast cancer gene therapy.

View Figures

View References

1	Shehzad A, Lee J and Lee YS: Curcumin in various cancers. Biofactors. 39:56–68. 2013.
2	Dhakal HP, Naume B, Synnestvedt M, et al: Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact. Histol Histopathol. 27:1315–1325. 2012.
3	Ashihara E: RNA interference for cancer therapies. Gan To Kagaku Ryoho. 37:2033–2041. 2010.(In Japanese).
4	Liu JL, Wei W, Tang W, et al: Silencing of lysyl oxidase gene expression by RNA interference suppresses metastasis of breast cancer. Asian Pac J Cancer Prev. 13:3507–3511. 2012.
5	Engebraaten O, Moen Vollan HK and Børresen-Dale AL: Triple-negative breast cancer and the need for new therapeutic targets. Am J Pathol. 183:1064–1074. 2013.
6	Li N, Zheng RS, Zhang SW, et al: Analysis and prediction of breast cancer incidence trend in China. Zhonghua Yu Fang Yi Xue Za Zhi. 46:703–707. 2012.(In Chinese).
7	Sheri A and Johnston S: New developments and future directions in systemic therapy. Clin Oncol (R Coll Radiol). 25:117–126. 2013.
8	Veeck J1, Noetzel E, Bektas N, et al: Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer. Mol Cancer. 7:832008.
9	Zhang X and Munster PN: New protein kinase inhibitors in breast cancer: afatinib and neratinib. Expert Opin Pharmacother. 15:1277–1288. 2014.
10	De Los Santos JF, Cantor A, Amos KD, et al: Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer. 119:1776–1783. 2013.
11	Taromaru GC, DE Oliveira VM, Silva MA, et al: Interaction between cyclooxygenase-2 and insulin-like growth factor in breast cancer: A new field for prevention and treatment. Oncol Lett. 3:682–688. 2012.
12	Park BW, Park S, Park HS, et al: Cyclooxygenase-2 expression in proliferative Ki-67-positive breast cancers is associated with poor outcomes. Breast Cancer Res Treat. 133:741–751. 2012.
13	Huang ZF, Massey JB and Via DP: Differential regulation of cyclooxygenase-2 (COX-2) mRNA stability by interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) in human in vitro differentiated macrophages. Biochem Pharmacol. 59:187–194. 2000.
14	Howe LR, Subbaramaiah K, Brown AM and Dannenberg AJ: Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer. 8:97–114. 2001.
15	Singh B and Lucci A: Role of cyclooxygenase-2 in breast cancer. J Surg Res. 108:173–179. 2002.
16	Oliveira VM, Piato S and Silva MA: Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium. Breast Cancer Res Treat. 95:235–241. 2006.
17	Gabbert H, Wagner R, Moll R and Gerharz CD: Tumor dedifferentiation: an important step in tumor invasion. Clin Exp Metastasis. 3:257–279. 1985.
18	Takahashi Y, Kawahara F, Noguchi M, et al: Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2. FEBS Lett. 460:145–148. 1999.
19	Sivula A, Talvensaari-Mattila A, Lundin J, et al: Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat. 89:215–220. 2005.
20	Bailey T, Biddlestone L, Shepherd N, et al: Altered cadherin and catenin complexes in the Barrett’s esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol. 152:135–144. 1998.
21	Hiraga T, Myoui A, Choi ME, et al: Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 66:2067–2073. 2006.
22	Musto P: Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res. 28:325–332. 2004.
23	Pai R, Szabo IL, Soreghan BA, et al: PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun. 286:923–928. 2001.
24	Liu XH, Kirschenbaum A, Yao S, et al: Upregulation of vascu larendothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis. 17:687–694. 1999.
25	Uefuji K, Ichikura T and Mochizuki H: Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenes is in gastric cancer. Clin Cancer Res. 6:135–138. 2000.
26	Bamba H, Ota S, Kato A, et al: Prostaglandins up-regulate vascu larendothelial growth factor production distict pathways in differentiated U937 cells. Biochem Biophys Res Commun. 273:487–491. 2000.
27	Tsurusaki T, Kanda S, Sakai H, et al: Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer. 80:309–313. 1999.
28	Su JL, Shih JY, Yen ML, et al: Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymph angiogenesis in lung adenocarcinoma. Cancer Res. 64:554–564. 2004.
29	Kubowicz P, Żelaszczyk D and Pękala E: RNAi in clinical studies. Curr Med Chem. 20:1801–1816. 2013.
30	Ghafouri-Fard S and Ghafouri-Fard S: siRNA and cancer immunotherapy. Immunotherapy. 4:907–917. 2012.
31	McCormick DL, Madigan MJ and Moon RC: Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res. 45:1803–1808. 1985.
32	Harris RE, Alshafie GA, Abou-Issa H and Seibert K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 60:2101–2103. 2000.
33	Nakatsugi S, Ohta T, Kawamori T, et al: Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazol[4,5-b]pyridine(PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res. 91:886–892. 2000.
34	Harris RE, Chlebowski RT, Jackson RD, et al: Women’s Health Initiative: Breast cancer and nonsteroidal anti-imflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res. 63:6096–6101. 2003.
35	Khuder SA and Mutgi AB: Breast cancer and NSAIDs use: a meta-analysis. Br J Cancer. 84:1188–1192. 2001.
36	Jana D, Sarkar DK, Maji A, et al: Can cyclo-oxygenase-2 be a useful prognostic and risk stratification marker in breast cancer? J Indian Med Assoc. 110:429–433. 2012.